Chronic Lymphocytic Leukemia

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (+)	TP53 deletion	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (+)	17p deletion	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (+)	17p deletion	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (+)	Wild type TP53	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (+)	TP53 deletion	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
Sensitivity (+)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
Sensitivity (+)	17p deletion	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
Sensitivity (+)	CD20 +	Chronic Lymphocytic Leukemia	Cyclophosphamide, Fludarabine, Rituximab
Sensitivity (+)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (+)	TP53 deletion	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (+)	17p deletion	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (+)	Wild type TP53	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (+)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Zanubrutinib
Sensitivity (+)	TP53 deletion	Chronic Lymphocytic Leukemia	Zanubrutinib
Sensitivity (+)	17p deletion	Chronic Lymphocytic Leukemia	Zanubrutinib
Sensitivity (+)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Acalabrutinib
Sensitivity (+)	TP53 deletion	Chronic Lymphocytic Leukemia	Acalabrutinib
Sensitivity (+)	17p deletion	Chronic Lymphocytic Leukemia	Acalabrutinib
Sensitivity (+)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Ibrutinib
Sensitivity (+)	TP53 deletion	Chronic Lymphocytic Leukemia	Ibrutinib
Sensitivity (+)	17p deletion	Chronic Lymphocytic Leukemia	Ibrutinib
Sensitivity (+)	TP53 deletion	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
Sensitivity (+)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
Sensitivity (+)	17p deletion	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
Sensitivity (+)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Idelalisib, Ofatumumab
Sensitivity (+)	TP53 deletion	Chronic Lymphocytic Leukemia	Idelalisib, Ofatumumab
Sensitivity (+)	17p deletion	Chronic Lymphocytic Leukemia	Idelalisib, Ofatumumab